Matthew Hobson, PhD is a Principal at Catalio Capital Management. Matthew joined Catalio at its founding in 2020 and primarily covers investments in therapeutics and diagnostics for their venture and private credit strategies. He currently represents Catalio as a board observer of multiple companies including Anagenex, Iambic Therapeutics, Octant, and Pink Dx. Prior to joining Catalio, Matthew was a Postdoctoral Fellow at the Johns Hopkins School of Medicine where he also earned a PhD in biophysics and biophysical chemistry, studying proteins involved in DNA replication and repair. Matthew holds a B.S. in chemistry and physics from Emory University.
